TGF-β1 mRNA expression in liver biopsy specimens and TGF-β1 serum levels in patients with chronic hepatitis C before and after antiviral therapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 3, 2005, Pages 271-277

  Marek, Bogdan ^a   Kajdaniuk, D ^a   Mazurek, U ^a   Janczewska Kazek, E ^a   Kos Kudla, B ^a   Strzalka, B ^a   Fila, A ^a   Niedziolka, D ^a   Beniowski, M ^a   Ostrowska, Z ^a   Borgiel Marek, H ^a   Kajdaniuk, J ^a   Sieminska, L ^a   Nowak, M ^a   Wilczok, T ^a   Pakula, D ^a   Filipczyk, P ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Hepatitis; Interferon; Liver; mRNA; Ribavirin; Transforming growth factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; MESSENGER RNA; PROTEINASE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA1; ANTIVIRUS AGENT; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG ANTAGONISM; DRUG COMBINATION; LIVER; METABOLISM;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 23844519824     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00644.x     Document Type: Article

References (37)

1. Kiyosawa K, Sodeyama Tanaka E (1990) Inter-relationship of blood transfusion, no-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology, 12, 671-675.
2. Lau JY (1994) Hepatitis C virus: from epidemiology and molecular virology to immunology. Hepatology, 20, 760-762.
3. Liang TJ, Rehermann B, Seef LB, Hoofnagle JH (2000) Pathogenesis, natural history, treatment and prevention of hepatitis C. Annals of Internal Medicine, 132, 296-305.
4. Tong MJ, El-Farra NS, Reikes AR (1995) Clinical outcomes after transfusion-associated hepatitis C. New England Journal of Medicine, 332, 1463-1466.
5. Friedman SC (2003) Liver-from bench to bedside. Journal of Hepatology, 38, 38-53.
6. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet, 349, 825-832.
7. Wickert L, Abiaka M, Bolkenius U, Gressner AM (2004) Corticos4eroids stimulate selectively transforming growth factor (TGF)-beta receptor type III expression in transdifferentiating hepatic stellate cells. Journal of Hepatology, 40, 69-76.
8. Olaso E, Friedman SL (1998) Molecular mechanisms of hepatic fibrogenesis. Journal of Hepatology, 29, 836-847.
9. Bachem MG, Riess U, Melchior R, Sell KM, Gressner AM (1989) Transforming growth factors (TGF alpha and TGF beta1) stimulate chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cells. FEBS Letters, 257, 134-137.
10. Gressner AM (1995) Cytokines and cellular crosstalk involved in the activation of fat-storing cells. Journal of Hepatology, 22, 28-36.
11. Bissel DM, Wang SS, Jarnagin WR, Roll FJ (1995) Cell-specific expression of transforming growth factor-beta in rat liver. Journal of Clinical Investigations, 96, 447-455.
12. Bachem MG, Meyer D, Melchior R, Sell KM, Gressner AM (1992) Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. Journal of Clinical Investigations, 89, 19-27.
13. Knittel T, Janneck T, Muller L, Fellmer P, Ramadori G (1996) Transforming growth factor betal - regulated gene expression of Ito cells. Hepatology, 24, 352-360.
14. Fausto N (2000) Liver regeneration. Journal of Hepatology, 32(Suppl. 1), 19-31.
15. Castilla A, Prieto J, Fausto N (1991) Transforming growth factors beta-1 and alpha in chronic liver disease. New England Journal of Medicine, 324, 933-940.
16. Annoni G, Weiner FR, Zern MA (1992) Increased transforming growth factor-betal gene expression in human liver disease. Journal of Hepatology, 14, 259-264.
17. Nelson DR, Gonzales-Peralta RP, Qian K, Xu Y, Marousis CG, Davis GL, Lau JY (1997) Transforming growth factor-betal in chronic hepatitis C. Journal of Viral Hepatitis, 4, 29-35.
18. Bedossa P, Poynard T, Mathurin P, Lemaigre G, Chaput JC (1993) Transforming growth factor beta1. In situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. Gut, 34, 146-147.
19. Roulot D, Durand H, Coste T, Rautureau J, Strosberg AD, Benarous R, Marullo S (1995) Quantitative analysis of transforming growth factor betal mes-senger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology, 21, 298-304.
20. Grungreiff K, Reinhold D, Ansorge S (1999) Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin and zinc in chronic hepatitis C patients treated with interferon-alpha. Cytokine, 11, 1076-1080.
21. Tsushima H, Kawata S, Tamura S et al. (1999) Reduced plasma transforming growth factor-betal levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. Journal of Hepatology, 30, 1-7.
22. Flisiak R, Maxwell P, Prokopowicz D, Timms PM, Panasiuk A (2002) Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor betal - possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepatogastroenterology, 49, 1369-1372.
23. Kanzler S, Baumann M, Schirmacher P et al. (2001) Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor beta. Journal of Viral Hepatitis, 8, 430-437.
24. Lu LG, Zeng MD, Wan MB et al. (2003) Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters. World Journal of Gastroenterology, 9, 2574-2578.
25. Flisiak R, Pytel-Krolczuk P, Prokopowicz D (2000) Circulating transforming growth factor betal as an indicator of hepatic function impairment of liver cirrhosis. Cytokine, 12, 677-681.
26. Scheuer PJ (1991) Classification of chronic viral hepatitis: a need for reassessment. Journal of Hepatology, 13, 372-374.
27. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium-thiocyanate phenol-chloroform extraction. Analytical Biochemistry, 162, 156-159.
28. Derynck R, Jarrett JA, Chen EY et al. (1985) Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature, 316, 701-705.
29. Ercolani L, Florence B, Denaro M, Alexander M (1988) Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. Journal of Biology and Chemistry, 263, 15335-15341.
30. Li D, Friedman SL (1999) Liver fibrogenesis and the role of hepatic stellate cells: new insights and pros-pects for therapy. Journal of Gastroenterology and Hepatology, 14, 618-623.
31. Bissel DM (1998) Hepatic fibrosis as wound repair: a progress report. Journal of Gastroenterology, 33, 295-302.
32. Cadranel JF, Rufat P, Degos F (2000) Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology, 32, 477-481.
33. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Doherty AJ, Angel P, Heath JK (1987) Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO Journal, 6, 1899-1904.
34. Marek B, Kajdaniuk D, Janczewska-Kazek E et al. (2003) Serum aminoterminal peptide of type III procollagen (PIIINP) and transforming growth factor-β1 (TGF-β1) levels in patients with chronic hepatitis B and C. Polish Archives of Internal Medicine, 6, 603-608.
35. Sobue S, Nomura T, Ishikawa T (2001) Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. Journal of Gastroenterology, 36, 544-551.
36. Star GA, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annual Review of Biochemistry, 67, 227-264.
37. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki K (1995) Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology, 22, 426-431.